| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 3
| Issue : 2 | Page : 127-131 |
|
|
Red carpeting the newer antidiabetics
Dilip Gude
Registrar, AMC, 3rd Floor, Medwin Hospital, Chirag Ali lane, Nampally, Hyderabad, Andhra Pradesh, India
Correspondence Address:
Dilip Gude
Registrar, Internal Medicine, Medwin Hospital, Nampally, Hyderabad, Andhra Pradesh 500 001
India
DOI: 10.4103/0976-500X.95507 PMID: 22629086
|
|
|
The rapidly increasing prevalence of diabetes on a global scale beseeches an urgent need for newer and better treatment options. Our better understanding of the pathophysiology of diabetes has enabled a continual churn out of newer antidiabetic agents with varying modes of action. Sodium-Glucose Transport Proteins-2 inhibitors, dipeptidyl peptidase IV inhibitors, glucagon-like peptide analogues, glucokinase activators, dual peroxisome proliferator-activated receptor agonists, monoclonal antibodies, and dopamine-2 receptor agonists either as monotherapy or combination therapy with the existing oral hypoglycemic agents compound our fight against diabetes. A review of the newer drugs targeting various aspects in the management of diabetes is presented. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
